Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
arcticnovartis
Fri, 03/06/2026 – 14:34
Read more about Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrat…
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
arcticnovartis
Fri, 02/27/2026 – 15:04
Read more about Novartis successfully completes acquisition of Av…
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis
Fri, 02/27/2026 – 12:34
Read more about Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
…
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis
Fri, 02/27/2026 – 12:34
Read more about Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
arcticnovartis
Wed, 02/25/2026 – 13:04
Read more about Novartis to build new radioligand therapy site in Denton, Texas, deliver…
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
arcticnovartis
Tue, 02/24/2026 – 13:19
Read more about New real‑world data reinforce earlier use of Pluvicto™ before chem…
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
arcticnovartis
Tue, 02/24/2026 – 13:19
Read more about New real‑world data reinforce earlier use of Pluvicto™ before chem…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
Mon, 02/23/2026 – 19:49
Read more about Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potenti…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
Mon, 02/23/2026 – 07:19
Read more about Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potenti…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
Mon, 02/23/2026 – 07:19
Read more about Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potenti…
